FORXIGA tablets are indicated as a once-daily oral medication to improve glycaemic control in adult patients
AstraZeneca Pharma India (AstraZeneca India), has announced the launch of FORXIGA(dapaglifozin), a breakthrough treatment for Type 2 diabetes mellitus.
FORXIGA belongs to a new class of Type 2 diabetes mellitus medication, a highly selective inhibitor of sodium-glucose co-transporter 2 (SGLT2). It has an unique insulin independent mode of action that helps remove excess glucose from the body via urine which is associated with reductions in glycated haemoglobin (HbA1c), weight and systolic blood pressure. Globally, FORXIGA is the first medicine in the new SGLT2 inhibitor class to gain regulatory approval for the treatment of Type 2 diabetes mellitus.
FORXIGA tablets are indicated as a once-daily oral medication to improve glycaemic control in adult patients with Type 2 diabetes mellitus. The drug is indicated to be used as an adjunct to diet and exercise in combination with other glucose-lowering medicinal products, including insulin, or as a monotherapy in metformin-intolerant patients. The drug is currently approved in more than 40 countries.
Mr Sanjay Murdeshwar, MD, AstraZeneca India said, "FORXIGA represents a significant advancement in the treatment of Type 2 diabetes mellitus with global safety and efficacy data of 4 years. It is an important addition to our innovative anti-diabetic portfolio; strengthening our commitment to transform patient care in diabetes by offering an additional treatment option for over 63 million diabetic patients in India."
Dr Bhavesh Kotak, vice-president, Medical and Regulatory Affairs, AstraZeneca India said, "Reaching treatment goals of diabetic patients continues to be a challenge in spite of multiple therapeutic options of oral and injectable anti diabetic agents. FORXIGA works by blocking reabsorption of glucose in the kidneys. Excess glucose gets excreted via urine helping patients achieve glycaemic control, a major treatment goal."
